Next, the in vitro experiments revealed that the tsRNA-GlyGCC inhibitor suppresses cell proliferation, migration, and formation of tumor spheres by modulating the protein expression of BCL2, BAX and cancer stem cells molecular markers (CD44,CD133, EphB2, LICAM, and LGR5). This evidence concerns the gene EPHB2 and neoplasm.